P. Den Teuling, Niek G. http://orcid.org/0000-0003-1026-5080
van den Heuvel, Edwin R. http://orcid.org/0000-0001-9157-7224
Aloia, Mark S.
Pauws, Steffen C. http://orcid.org/0000-0003-2257-9239
Funding for this research was provided by:
Philips
Article History
Received: 14 January 2021
Accepted: 15 September 2021
First Online: 1 December 2021
Declarations
:
: The data collection and analysis were approved by the Philips Research internal review board; the Internal Committee for Biomedical Experiments (ICBE), Reference number ICBE-2-14816, on 6 May 2019. All methods were carried out in accordance with relevant guidelines and regulations. The users registering with the DreamMapper application were invited to agree with the Terms of Service and provide consent to the use of their data before they could use the application. Before consent was collected, the users were invited to consult the privacy notice in order to be informed about their data rights, as well as Philips’ data practices. The privacy notice was accessible to the users during the consent moment, and after consent via the DreamMapper application.Users could withdraw consent at all times by following the indications in the privacy notice. The privacy notice contained information on the right to withdraw consent, among other rights.It is important to note that only those users of the DreamMapper application who consented for their data to be used for research and product improvement purposes, were included in the study.
: Not applicable.
: N.T., M.A., and S.P. are employees of Philips. M.A. is stockholder at Philips. E.H. declares no competing interests.